Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.
Elafibranor, sold under the brand name Iqirvo, is a medication used for the treatment of primary biliary cholangitis.
Elafibranor is a dual PPARα/δ agonist. Elafibranor and its main active metabolite GFT1007 are peroxisome proliferator-activated receptor (PPAR) agonists, both of which activate PPAR-alpha, PPAR-gamma, and PPAR-delta in vitro.
Discovered by embedding cosine similarity (sentence-transformers MiniLM, 384-dim).